In this phase 2 double-blind trial, we randomly assigned adults with treatment-resistant depression to receive a single dose of a proprietary, synthetic formulation of psilocybin at a dose of 25 mg, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback